Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.

Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy

Greer, Ian A., Nelson-Piercy, Catherine · 2005 · Blood

Abstract

To assess the safety and efficacy of low-molecular-weight heparins (LMWHs) for thromboprophylaxis and treatment of venous thromboembolism (VTE) in pregnancy, a systematic review of studies to the end of 2003 was undertaken. Data on VTE recurrence and side effects were extracted and cumulative incidences of VTE and adverse effects calculated. Of 81 reports identified, 64 reporting 2777 pregnancies were included. In 15 studies (174 patients) the indication for LMWH was treatment of acute VTE, and in 61 studies (2603 pregnancies) it was thromboprophylaxis or adverse pregnancy outcome. There were no maternal deaths. VTE and arterial thrombosis (associated with anti-phospholipid syndrome) were reported in 0.86% (95% confidence interval [CI], 0.55%-1.28%) and 0.50% (95% CI, 0.28%-0.84%) of pregnancies, respectively. Significant bleeding, generally associated with primary obstetric causes, occurred in 1.98% (95% CI, 1.50%-2.57%), allergic skin reactions in 1.80% (95% CI, 1.34%-2.37%), heparin-induced thrombocytopenia in 0%, thrombocytopenia (unrelated to LMWH) in 0.11% (95% CI, 0.02%-0.32%), and osteoporotic fracture in 0.04% (95% CI, < 0.01%-0.20%) of pregnancies. Overall, live births were reported in 94.7% of pregnancies, including 85.4% in those receiving LMWH for recurrent pregnancy loss. LMWH is both safe and effective to prevent or treat VTE in pregnancy.

Overview

Integrity signals

Registry

Crossref · 10.1182/blood-2005-02-0626

Cites

112 of 112 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 109 references

Cited by

See all 797

Metadata

Authors
Greer, I. A., & Nelson-Piercy, C.
Affiliations
  • University of Glasgow (GB)
  • From the University of Glasgow, Glasgow, United Kingdom; and Guy's and St Thomas' Hospitals Trust and Queen Charlotte's Hospital, London, United Kingdom.
Venue
Blood
Published
2005-07-15
Volume
106
Issue
2
Pages
401-407
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2029235302
Cited by
797
References
109
Citations by year
2026: 15 · 2025: 21 · 2024: 33 · 2023: 22 · 2022: 35 · 2021: 37 · 2020: 31 · 2019: 36 · 2018: 38 · 2017: 41 · 2016: 35 · 2015: 56 · 2014: 43 · 2013: 50 · 2012: 62
FWCI
7.70
Type
journal article
Language
en
Open access
closed
Locations
  • Blood (publishedVersion)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (submittedVersion)
Funders
North Carolina State University
Topics
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
  • Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
  • Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
Keywords
low molecular weight heparin, venous thromboembolism, pregnancy, thromboprophylaxis, anticoagulant safety, adverse pregnancy outcomes, arterial thrombosis, antiphospholipid syndrome, bleeding complications, heparin-induced thrombocytopenia, osteoporotic fractures, recurrent pregnancy loss, live birth
MeSH terms
Abortion, Habitual, Anticoagulants, Female, Fibrinolytic Agents, Heparin, Low-Molecular-Weight, Humans, Infant, Newborn, Pregnancy, Pregnancy Complications, Cardiovascular, Pregnancy Outcome, Recurrence, Safety, Thromboembolism

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. https://app.cochat.ai/papers/10.1182/blood-2005-02-0626
The paper
Greer, I. A., & Nelson-Piercy, C. (2005). Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood. https://doi.org/10.1182/blood-2005-02-0626

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.